Zimmer Biomet Holdings Inc Dossier
|
SectorHealth Care IndustryMedical Devices Beta (adjusted)0.64 Intrinsic Value $105.88median of 6 methods · middle span $99-$127based on filings through 30 Jun 2026 Market Price $88.83Price as of 30 Sep 2026 UndervaluedIntrinsic value is 19% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $16.9B Enterprise Value $24B Shares Outstanding 194M diluted Moat Rating None Next Earnings Date5 Nov 2026 Last ex-dividend25 Jun 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Zimmer Biomet entered the second half of 2026 with improving top-line momentum: second-quarter organic constant-currency growth reached 4.0%, management raised full-year revenue and adjusted-EPS guidance, and the technology-oriented portfolio grew 21.5% at constant currency. The offset is mixed operating quality: quarterly adjusted EPS was unchanged year over year, adjusted operating margin declined to 25.7% from 27.8%, and total knee growth was only 0.1% at constant currency, including a 1.5% international decline. The U.S. sales transformation, acquisition integration, pricing pressure, tariffs, product quality, and regulatory execution remain material swing factors. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$93.00 Mean target$107.57 High · most bullish analyst$130.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $93.0024% The U.S. sales transformation disrupts customer relationships, international knee weakness broadens, innovation adoption slows, or acquisition and restructuring execution costs remain elevated. Organic growth falls below guidance, adjusted EPS misses the lower bound, and margin pressure persists. Regulatory, product-quality, tariff, pricing, litigation, or supply-chain pressures could deepen the downside. Base CaseCentral scenario $107.5757% Matches the consensus meanZimmer Biomet delivers within its updated FY2026 ranges of 2.25%-3.25% organic constant-currency revenue growth and $8.47-$8.59 adjusted diluted EPS. Technology and hip growth offset subdued knee performance, while commercial-transformation and integration costs constrain near-term margin expansion. Bull CaseUpside scenario $130.0019% Innovation adoption accelerates across ROSA, digital, data, and recently launched products; the U.S. commercial transformation improves selling effectiveness; hip growth remains healthy; and companywide organic growth stays above the updated FY2026 range while margins recover. Continued free-cash-flow generation and share repurchases would amplify per-share outcomes. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |